Legal & General Group Plc Buys Shares of 26,822 Harrow, Inc. $HROW

Legal & General Group Plc purchased a new position in Harrow, Inc. (NASDAQ:HROW - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 26,822 shares of the company's stock, valued at approximately $1,139,000. Legal & General Group Plc owned about 0.07% of Harrow at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of HROW. BlackRock Inc. purchased a new stake in Harrow during the second quarter valued at $116,373,000. Vanguard Group Inc. increased its stake in shares of Harrow by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company's stock worth $94,162,000 after purchasing an additional 50,889 shares in the last quarter. Luxor Capital Group LP raised its holdings in Harrow by 22.0% in the 1st quarter. Luxor Capital Group LP now owns 1,119,400 shares of the company's stock worth $39,470,000 after purchasing an additional 201,859 shares during the period. Geode Capital Management LLC lifted its position in Harrow by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 785,089 shares of the company's stock valued at $38,477,000 after purchasing an additional 9,445 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Harrow by 56.4% during the first quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company's stock valued at $20,428,000 after purchasing an additional 208,972 shares during the period. 72.76% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Harrow

In related news, insider Amir Shojaei sold 11,250 shares of the company's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $40.00, for a total transaction of $450,000.00. Following the transaction, the insider directly owned 11,250 shares in the company, valued at approximately $450,000. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 12.80% of the company's stock.

Harrow Stock Performance

Shares of NASDAQ HROW opened at $38.54 on Tuesday. The company has a debt-to-equity ratio of 19.70, a quick ratio of 2.08 and a current ratio of 2.24. The company has a market cap of $1.44 billion, a P/E ratio of -38.54 and a beta of 0.24. The firm's fifty day moving average is $40.80 and its two-hundred day moving average is $39.08. Harrow, Inc. has a 52-week low of $28.54 and a 52-week high of $54.85.

Harrow (NASDAQ:HROW - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.28). Harrow had a negative return on equity of 38.00% and a negative net margin of 13.51%.The company had revenue of $70.66 million during the quarter, compared to analysts' expectations of $70.35 million.

Analysts Set New Price Targets

Several research analysts have recently commented on HROW shares. Cantor Fitzgerald decreased their price objective on Harrow from $91.00 to $88.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 13th. Wall Street Zen raised shares of Harrow from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. BTIG Research reissued a "buy" rating and issued a $63.00 price objective on shares of Harrow in a research note on Tuesday, August 11th. Zacks Research downgraded shares of Harrow from a "hold" rating to a "strong sell" rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Harrow in a report on Monday, July 20th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $69.43.

About Harrow

Harrow Health, Inc NASDAQ: HROW is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.

Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow, Inc. (NASDAQ:HROW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.